Navigation Links
LS9 Secures $25 Million in Latest Round of Funding
Date:9/24/2009

LS9, Inc., the Renewable Petroleum Company™, today announced it successfully completed a $25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

South San Francisco, CA (PRWEB) September 24, 2009 -- LS9, Inc., the Renewable Petroleum Company™, today announced it successfully completed a $25 million round of funding. Participating investors included CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; Flagship Ventures; Khosla Ventures and Lightspeed Venture Partners.

In May this year, LS9 announced a strategic partnership with Procter & Gamble to support the joint development and commercialization of LS9 technology to produce key chemicals used within the P&G portfolio of consumer products.

"LS9 is proud to attract recognized leaders in consumer products and transportation fuels," said Bill Haywood, CEO of LS9. "This clearly illustrates the future potential of LS9 in both the sustainable chemicals and renewable transportation fuels sectors."

LS9's revolutionary technology uses a one-step fermentation process to convert renewable plant-based materials into a portfolio of UltraClean™ fuels and high-value, sustainable chemicals. "LS9 represents one of the cleanest and most efficient technologies available in the production of high-value, low-carbon, cost effective fuels, and this funding will accelerate our ability to demonstrate commercial level production," said Stephen del Cardayre, Vice President, Research and Development, LS9.

LS9 is currently producing UltraClean™ Diesel at its pilot facility. UltraClean™ Diesel has achieved U.S. and Brazilian performance standards for on-road use, and achieves an 85% reduction in green house gas emissions. In addition, LS9 UltraClean™ Diesel contains no carcinogens, such as benzene, and only trace amounts of sulfur.

LS9's technology also makes it possible to create superior products that can uniquely achieve optimal overall performance. LS9 has demonstrated its ability to modify the genetic makeup of its microorganisms and precisely tailor LS9 end products to have improved fuel properties such as cetane, volatility, oxidative stability and cold-flow. LS9 will have demonstration scale production of UltraClean™ Diesel in 2010.

In addition to low-carbon transportation fuels, LS9's one-step fermentation process is capable of producing chemicals used in making industrial and consumer products. LS9 previously announced a partnership with Procter & Gamble to jointly develop and commercialize LS9 technology for use in the production of key consumer chemicals within the Procter & Gamble portfolio.

For more information about LS9 products and capabilities, please visit www.ls9.com.

About LS9
LS9, Inc., the Renewable Petroleum Company™, is a privately-held industrial biotechnology company pursuing the commercial development of renewable fuels and chemicals. LS9 is applying synthetic biology to produce proprietary biofuels that are compatible with existing fuel distribution and consumer infrastructure, as well as high-value industrial chemicals. LS9 is the pioneer in the commercial development of fermentation derived hydrocarbon biofuels and its patent-pending Renewable Petroleum(TM) products are custom engineered in the lab to address immediate market needs for clean energy alternatives to petroleum. The company was founded in 2005 and venture capital firms Flagship Ventures, Khosla Ventures, and Lightspeed Venture Partners have provided funding to date. LS9 is headquartered in South San Francisco, California. For more information about LS9 products and capabilities, please visit www.ls9.com.

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2936734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Secures Committed Equity Financing Facility
2. OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm
3. Cappella Inc. Secures $17.3 Million Series C Investment
4. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
5. Sinobiopharma Secures Rights to Seven Key Patents
6. Aerovance Secures $38 Million in Equity Financing
7. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
8. Pearl Therapeutics Secures $8 Million in Debt Financing
9. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Northwest Biotherapeutics Secures $700,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an ... the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations ...
(Date:2/11/2016)... Buffalo, New York (PRWEB) , ... February 11, ... ... and analytical instruments for more than 150 years, continues today to pursue the ... to its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... Early-career researchers from ... , Uganda and Yemen ... nutrition   Indonesia , Nepal ... Yemen are being honored for their accomplishments in ... celebrated for mentoring young women scientists who are pursuing careers in agriculture, ...
Breaking Biology Technology:
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):